Format

Send to

Choose Destination
Int J Mol Cell Med. 2015 Summer;4(3):143-51.

Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy.

Author information

1
Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Abstract

CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating CD19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. Moreover, several anti- CD19 mAbs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.

KEYWORDS:

Anti-CD19; B-cell lymphoma; anti-CD19 sFv; blinatumumab; monoclonal antibodies

PMID:
26629482
PMCID:
PMC4644525

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center